Navigation Links
SimBioSys Utilizes Revolutionary Hardware Technology to Open New Frontiers in Molecular Modeling
Date:4/24/2008

TORONTO, April 24 /PRNewswire/ - SimBioSys, a leader in the field of rational drug discovery software, today announced it has exploited parallel computer architecture to dramatically speed up the process of virtual screening and docking. This advance positively impacts the speed by which scientists can perform virtual screening calculations.

Through porting and optimization of SimBioSys' eHiTS software on the IBM(R) BladeCenter(R) QS2 based on the multi-core Cell Broadband Engine (Cell/B.E.) processor, the new "eHiTS Lightning" software application has demonstrated accelerated throughput of up to 30x faster than the application running on a traditional processor configuration. With this improvement in performance, much larger libraries of chemical compounds can be screened in a comparable time, or alternatively, the algorithms can be applied to generate results with higher accuracy in a more manageable timeframe than previously available.

"Our decision to support our eHiTS software on the Cell Broadband Engine was driven by the enormous gains in throughput that the processor could deliver," said Zsolt Zsoldos, chief technology officer, SimBioSys. "With a well-defined commercial marketplace supporting the innovations and extensions to the chip technology, it was clear the Cell/B.E. processor has longevity and a product roadmap to sustain our own needs to innovate. eHiTS Lightning running on a single Cell/B.E processor will provide throughput equivalent to a cluster of about thirty 2GHz Intel chips. Alternatively, it will allow greater accuracy in a much reduced timescale. In either case, scientists are supported in their search for new drug candidates through accelerated discovery." For more in-depth information see this white-paper:

http://www.simbiosys.ca/science/white_papers/eHiTS_on_the_Cell.pdf

Virtual screening is the evaluation of very large libraries of compounds using algorithms and computer programs to filter massive amounts of compounds to a number that can be synthesized, purchased and tested. The main goal of this approach is to identify novel chemical structures that yield a unique pharmacological profile.

"The Cell Broadband Engine processor was specifically designed to offer extreme performance to accelerate compute-intensive tasks," said Jim Comfort, vice president, IBM Systems and Technology Group. "This feature, combined with the eHiTS software, allows SimBioSys to optimize its drug research and discovery software platform. This life science advancement is just one example of how Cell/B.E. and IBM technology work together to help organizations establish a competitive advantage."

About SimBioSys:

SimBioSys is a recognized leader in the field of rational drug discovery software. Providing a wide range of software solutions, they are focused on the development of scientific software solutions to facilitate the drug discovery process. They retain a constant focus on the innovation of algorithms to provide improved throughput and accuracy in the fields of flexible docking tools for virtual screening and de novo structure design. While developing software to enable computer-assisted synthetic accessibility and retrosynthetic analysis they support chemists through the challenges of organic synthesis. With attention to detail, ease-of-use and improved productivity SimBioSys have become a market leader.


'/>"/>
SOURCE SimBio Sys Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
2. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
3. Cooler Solutions and Leading Research Hospital to Design Revolutionary Osteoporosis Diagnosis Device
4. FDA Clears Biospace meds Revolutionary Low Dose Xray Imager
5. Webcam MD - Launch of revolutionary web-based medical technology
6. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
7. NASA MidSTAR-1 successful technologies may be revolutionary
8. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
9. Novel Technology Breaks Through Cancer Pain
10. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
11. Advanced Cell Technology Announces Proposed Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
Breaking Biology Technology:
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):